Clinical Trials Directory

Trials / Unknown

UnknownNCT02649660

Lipidomics and Functional Analyses of Platelets in Fabry Disease

Status
Unknown
Phase
Study type
Observational
Enrollment
32 (estimated)
Sponsor
Spital Linth · Other Government
Sex
All
Age
18 Years – 65 Years
Healthy volunteers
Accepted

Summary

This study aims to evaluate whether platelets are biochemically and functionally altered in Fabry disease (FD) and therefore possibly implicated in FD manifestations such as cerebrovascular events. To test this hypothesis the investigators aim to compare platelet and plasma lipid profiles, as well as platelet function and coagulation parameters of FD patients and healthy controls.

Detailed description

Fabry disease (FD) is a severe X-linked inborn error of the lysosomal glycosphingolipid metabolism. FD patients have significantly increased risks for cardiac and cerebrovascular events, which can also occur early and in absence of the typical FD symptoms. However, the pathophysiological mechanisms leading to vascular occlusion and ischemia in FD are largely unclear. Prevention of recurrent cerebrovascular events is usually based on empirical anti-platelet therapy. Prothrombotic states and partially activated platelets have been reported for FD patients. Platelets contain glycosphingolipids, including globotriaosylceramide (Gb3), and have lysosomal α-galactosidase activity. To investigate whether the lack of or the reduced α-galactosidase enzyme activity present in Fabry disease affects platelet lipid metabolism the investigators plan to perform LC-MS-based lipidomics analyses of platelets and plasma in FD patients and healthy controls. To assess whether platelets are functionally altered in FD, the investigators aim to determine the activation status, activability, aggregability and other parameters along with plasma markers of coagulation using flow cytometry, aggregometry and immunoassays.

Conditions

Timeline

Start date
2015-10-01
Primary completion
2017-12-31
Completion
2017-12-31
First posted
2016-01-07
Last updated
2017-05-08

Locations

2 sites across 1 country: Switzerland

Source: ClinicalTrials.gov record NCT02649660. Inclusion in this directory is not an endorsement.